Corporate Background
.....................................................................................

Download the Oculus backgrounder information sheet.
(PDF: 141 KB)

Current Press Releases
.....................................................................................

August 7, 2008
Oculus Innovative Sciences to Present at Canaccord Adams 28th Annual Global Growth Conference

August 5, 2008
Oculus Innovative Sciences Reports 59% Increase in First Quarter Product Revenue

July 29, 2008
Oculus Innovative Sciences Announces Fiscal First Quarter Financial Results and Corporate Update Release and Conference Call

July 16, 2008
Oculus Innovative Sciences' CEO and Founder Named One of Pharmaceutical Executive's 2008 "Emerging Pharma Leaders"

July 1, 2008
Oculus Innovative Sciences Announces Positive Results from Abstract Evaluating the Use of Microcyn® Technology in Treatment of Atopic Dermatitis

June 23, 2008
Oculus Innovative Sciences Announces Agreement With Bayer (Sichuan) Animal Health Co. Ltd. for Development of Microcyn® Technology Use in Chinese Animal Market

June 19, 2008
Oculus Innovative Sciences Announces Agreement with Bayer Australia Limited for Development of Microcyn® Technology Use in Australian Animal Market

June 17, 2008
Oculus Innovative Sciences Announces Development of Microcyn®-Based Hydrogel Formulation

June 16, 2008
Oculus Innovative Sciences Announces Breakthrough Antimicrobial Formulation for Over-The-Counter Non-Wound Market to be Launched in U.S. Without Pre-Approval by the FDA

June 11, 2008
Oculus Innovative Sciences Announces Fiscal Fourth Quarter and Full Year 2008 Financial Results and Corporate Update

June 5, 2008
Oculus Innovative Sciences Announces Fiscal Fourth Quarter and Full Year 2008 Financial Results and Corporate Update Release and Conference Call

June 4, 2008
Oculus Innovative Sciences Files for Patent Protection on Breakthrough Wound Care Device to Accelerate Wound Healing

June 2, 2008
Oculus Innovative Sciences Announces Market Assessment of Near-Term Commercialization Opportunities in the United States for Dermacyn™ Wound Care

May 28, 2008
Oculus Innovative Sciences Announces Publication of Microcyn® Technology Post-Caesarean Section Wound Study in Indian Medical Gazette

May 15, 2008
Oculus Innovative Sciences to Participate in Third Congress of the World Union of Wound Healing Societies in Toronto

May 5, 2008
Oculus Innovative Sciences Announces Initial Chinese Commercialization Plan for Launch of Microcyn® Technology

April 23, 2008
Oculus Innovative Sciences Appoints Michelle Carpenter, JD, RAC, as Vice President of Regulatory Affairs and Quality

April 17, 2008
Oculus Innovative Sciences' CEO and Founder Hoji Alimi Featured on NASDAQ CEO Signature Series

April 15, 2008
Oculus Innovative Sciences Announces Publication of Microcyn® Technology Diabetic Wound Study in Journal of College of Physicians and Surgeons Pakistan

Archived Press Releases
.....................................................................................

March 28, 2008
Oculus Innovative Sciences, Inc., Announces $13.9 Million Securities Offering

March 27, 2008
Oculus Innovative Sciences Receives Chinese SFDA Regulatory Approval of Microcyn® Technology

March 17, 2008
Oculus Innovative Sciences Announces Positive Results From Three Abstracts Evaluating the Use of Microcyn® Technology in Diabetic Foot Ulcers

March 14, 2008
Oculus Innovative Sciences Announces Additional Phase II Data for Microcyn® Technology in Mildly Infected Diabetic Foot Ulcers

March 12, 2008
Oculus Innovative Sciences Announces Acceptance of Three Abstracts on the use of Microcyn® Technology in Diabetic Foot Ulcers by DFCon 08

March 11, 2008
Oculus Innovative Sciences to Announce Additional Phase II Data and Data from Two Recent International Studies at DFCon 08

February 27, 2008
Oculus Innovative Sciences Schedules Conference Call Today to Discuss Positive Top-Line Phase II Data with Microcyn® Technology in Mildly Infected Diabetic Foot Ulcers

February 27, 2008
Oculus Innovative Sciences Announces Positive Top-Line Phase II Data with Microcyn® Technology in Mildly Infected Diabetic Foot Ulcers

February 14, 2008
Oculus Innovative Sciences to Present at the Roth Capital Partners 20th Annual OC Growth Stock Conference

February 7, 2008
Oculus Innovative Sciences Announces Fiscal Third Quarter 2008 Quarterly Results and Clinical Update

February 5, 2008
Oculus Schedules Fiscal Third Quarter 2008 Financial Results Release and Conference Call

January 29, 2008
Oculus Innovative Sciences Announces Agreement with Animal Health International for North American Distribution of Microcyn®-Based Vetericyn™ Wound Spray

January 24, 2008
Oculus Innovative Sciences Awarded Damages by Federal Court in Intellectual Property Rights Litigation

January 22, 2008
Top-Line Data from Oculus Innovative Sciences' Phase II Trial to Be Presented at DFCon 08 (Diabetic Foot Global Conference) on March 14, 2008

January 17, 2008
Oculus Innovative Sciences, Inc. Appoints Gregg Alton to its Board of Directors

January 3, 2008
Oculus Innovative Sciences Completes Patient Treatment and Follow-up in Its Phase II Clinical Trial in Mildly Infected Diabetic Foot Ulcers

» Click Here For More Archived Press Releases

Upcoming Events
.....................................................................................

For a full list of trade shows and conferences, click here.

Clinical Studies
.....................................................................................

The Journal for Vascular Ultrasound
(December 2006)
Nonsurgical Management of Chronic Wounds in
Patients With Diabetes
(PDF: 108 KB)

Wounds (September 2006)
Super-Oxidized Solution (SOS) Therapy for Infected Diabetic Foot Ulcers
(PDF: 256 KB)

Diabetic Microvascular Complications Today
(May/June 2006)
Superoxidized Water Improves Wound Care Outcomes in Diabetic Patients
(PDF: 192 KB)

Journal of Hospital Infection (2005)
Microcyn^®: a novel super-oxidized water with neutral pH and disinfectant activity
(PDF: 256 KB)

White Papers
.....................................................................................

Effect of Electrolyzed Water on Wound Healing
(PDF: 550 KB)

Media Coverage
.....................................................................................

September 10, 2008
Medical Device Daily
Oculus cuts costs in advance of U.S. launch of Microcyn
(PDF: 88 KB)

August 1, 2008
FOX Business News: America's Nightly Scoreboard
The following video is available in Windows® Media Player, and RealPlayer®. Click on the links below to view the videos in your preferred format.

»Play	»Play

June 9, 2008
North Bay Business Journal
Device expected to greatly widen Oculus’ market
(PDF: 124 KB)

April 16, 2008
NASDAQ CEO Signature Series: Interview with Hoji Alimi
The following video is available in Windows® Media Player, and RealPlayer®. Click on the links below to view the videos in your preferred format.

»Play	»Play

February 27, 2008
Bloomberg
Oculus Treatment Effective Against Diabetic Foot Infections
(PDF: 16 KB)

June 2007
International Immunopharmacology
Super-oxidized solution inhibits IgE-antigen-induced degranulation and cytokine release in mast cells
(PDF: 740 KB)

June 4, 2007
Diabetes Health
It's a Wash: New Antimicrobial Solution Called Microcyn May Help Cure Diabetic Ulcers

May 24, 2007
The Daily Mail
Scientists create 'miracle water' that kills infections and MRSA
(PDF: 228 KB)

May 24, 2007
BBC News
Firm makes 'healing super-water'
(PDF: 84 KB)

May 23, 2007
BBC Radio Five Live
Hoji Alimi speaks about the Microcyn^® Technology on BBC Radio Five Live. Click to listen now.

Note: If you have problems accessing the MP3 file, PC users may need to right click on the the link and "Save Target As." After you have saved the file, open it in your preferred media player such as Windows^® Media Player or RealPlayer^®.

May 23, 2007
New Scientist
Bugs struck down by 'super-oxidised' water
(PDF: 352 KB)

March 2007
The International Journal of Lower Extremity Wounds
Clinical Outcomes of Wide Postsurgical Lesions in the Infected Diabetic Foot Managed...
(PDF: 232 KB)

September 2006
Wounds
Super-Oxidized Solution (SOS) Therapy for Infected Diabetic Foot Ulcers
(PDF: 256 KB)

August 2006
Podiatry Today
Emerging Innovations In Treatment
(PDF: 244 KB)

January 2006
Wounds
Clinical Experience with a New, Stable, Super-Oxidized Water in Wound Treatment
(PDF: 528 KB)

August 5, 2005
The New York Times
As New Products Arrive, Wound Care Sales Grow
(PDF: 64 KB)

June, 2005
Dermatology Times
Super-oxidized water kills bacteria; demonstrates potential for healing
(PDF: 88 KB)

June 6, 2005
Outlook India
H2O's Healing Touch - Chronic wounds now find a cure, courtesy Microcyn^®
(PDF: 495 KB)

June 1, 2005
Coast to Coast
Hoji Alimi speaks about the Microcyn^® Technology on Coast to Coast AM radio. Click to listen now.

Note: If you have problems accessing the MP3 file, PC users may need to right click on the the link and "Save Target As." After you have saved the file, open it in your preferred media player such as Windows^® Media Player or RealPlayer^®.

Oculus on FOX News
The following video is available in Windows^® Media Player, and RealPlayer^®. Click on the links below to view the videos in your preferred format.

»Play	»Play

May 17, 2005

Paul Harvey mentions Microcyn^® on his Tuesday noon show. Listen now using Windows Media Player.

May 16, 2005

Super Water Kills Bugs Dead - A California company has figured out how to use two simple materials....
(PDF: 65 KB)

March 26, 2005

'Ion man' seeks to tap acceptance for his water solution - A souped-up form of water has been overlooked as a killer of lethal viruses and bacteria....
(PDF: 120 KB)

Oculus on ABC News
The following video is available in Apple^® QuickTime, Windows^® Media Player, and RealPlayer^®. Click on the links below to view the videos in your preferred format.

»Play	»Play	»Play

February 10, 2005
Read What Forbes Magazine says about the Microcyn^® Technology.
(PDF: 64 KB)

November 9, 2004
PESTICIDE.NET - Super Oxidized Water Registered By EPA As A Hard-Surface Disinfectant
(PDF: 120 KB)

FAIR USE NOTICE: These articles and news reports may contain copyrighted material, the use of which may or may not have been specifically authorized by the copyright owner. This material is being made available in efforts to advance the understanding of scientific and medical issues. It is believed that this constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed without profit to those who have expressed a prior interest in receiving the included information for research, comment, discussion and educational purposes by visiting the Oculus web site. If you wish to use copyrighted material from these reports for purposes of your own that go beyond 'fair use', you must obtain permission from the copyright owner.

This web page contains forward-looking statements that involve risks and uncertainties. These forward-looking statements relate to, among other things, regulatory approvals, plans and timing for the introduction of our products, statements about future market conditions, supply and demand conditions, revenues, gross margins, operating expenses, profits and other expectations, intentions and plans that are not historical fact.

Our expectations as expressed at this web site depend upon our ability to develop, manufacture, obtain regulatory approval and supply and sell products that meet defined specifications. When used, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and in the health sciences market. In light of the many risks and uncertainties surrounding this market, you should understand that we cannot assure you that the forward-looking statements contained herein will be realized.